Loading...

NBY NOVABAY PHARMACEUTICALS INC Capital Structure Changes 8-K Filing

NVBY

NBY

NOVABAY PHARMACEUTICALS INC

(NBY)

2026 8-K

Management Changes

Name Change Announcement

Corporate Changes Update

Stock Split Notice

Stock Split Approved

New Auditor Engaged

Accountant Change

Stock Sale Agreement

Securities Agreement

Stock Preferences Update

Compliance Regained

Major Stock Changes

CEO Resignation

Special Dividend Announcement

Special Cash Dividend

Investment Agreement

Company Liquidation

Settlement Agreements

Advisory Agreement

Asset Sale Update

CEO Contract Extension

Special Meeting Update

Special Meeting Results

Asset Sale Update

Asset Sale Update

Asset Sale Announcement

Asset Sale Agreement

Public Offering

Earnings Report

Warrant Reprice Transactions

Reverse Stock Split

Sale of Subsidiary

Delisting Notice

Update Presentation

Delisting Notice

Completion of Asset Sale

Entry into a Material Defin...

License Agreement with Sono...

Warrant Reprice Transactions

Management Extension

Amendment to Bylaws and Ann...

Private Placement

Private Placement

Resignation and Appointment

External Links:

On January 20, 2026, NovaBay Pharmaceuticals, Inc. entered into an ATM Sales Agreement to potentially sell up to $100 million of its common stock through Virtu Americas LLC, with a commission of up to 2.0% on sales.

AI Assistant

NOVABAY PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.